IS7010A - Lyfjaform ókristallaðs nelfinavir mesylate - Google Patents

Lyfjaform ókristallaðs nelfinavir mesylate

Info

Publication number
IS7010A
IS7010A IS7010A IS7010A IS7010A IS 7010 A IS7010 A IS 7010A IS 7010 A IS7010 A IS 7010A IS 7010 A IS7010 A IS 7010A IS 7010 A IS7010 A IS 7010A
Authority
IS
Iceland
Prior art keywords
crystalline
pharmaceutical form
nelfinavir mesylate
nelfinavir
mesylate
Prior art date
Application number
IS7010A
Other languages
English (en)
Inventor
Howard Infeld Martin
Phuapradit Wantanee
Hargovindas Shah Navnit
Zhang Lin
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of IS7010A publication Critical patent/IS7010A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS7010A 2001-05-03 2003-10-30 Lyfjaform ókristallaðs nelfinavir mesylate IS7010A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28841001P 2001-05-03 2001-05-03
PCT/EP2002/004711 WO2002089835A2 (en) 2001-05-03 2002-04-29 Pharmaceutical dosage form of amorphous nelfinavir mesylate

Publications (1)

Publication Number Publication Date
IS7010A true IS7010A (is) 2003-10-30

Family

ID=23106974

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7010A IS7010A (is) 2001-05-03 2003-10-30 Lyfjaform ókristallaðs nelfinavir mesylate

Country Status (37)

Country Link
US (1) US7014866B2 (is)
EP (1) EP1390063B1 (is)
JP (1) JP4101661B2 (is)
KR (1) KR100554816B1 (is)
CN (1) CN1255185C (is)
AR (1) AR034320A1 (is)
AT (1) ATE282428T1 (is)
BG (1) BG108311A (is)
BR (1) BR0209325A (is)
CA (1) CA2444116C (is)
CZ (1) CZ20033211A3 (is)
DE (1) DE60201988T2 (is)
EA (1) EA006627B1 (is)
EC (1) ECSP034827A (is)
ES (1) ES2231717T3 (is)
GE (1) GEP20053466B (is)
GT (1) GT200200079A (is)
HK (1) HK1070285A1 (is)
HR (1) HRP20030873B1 (is)
HU (1) HU229938B1 (is)
IL (2) IL158306A0 (is)
IS (1) IS7010A (is)
JO (1) JO2401B1 (is)
MA (1) MA27018A1 (is)
MX (1) MXPA03009971A (is)
MY (1) MY128509A (is)
NO (1) NO20034689D0 (is)
NZ (1) NZ528689A (is)
PA (1) PA8544501A1 (is)
PE (1) PE20021159A1 (is)
PL (1) PL366998A1 (is)
PT (1) PT1390063E (is)
RS (1) RS83503A (is)
SK (1) SK14572003A3 (is)
TW (1) TWI234461B (is)
UA (1) UA76463C2 (is)
WO (1) WO2002089835A2 (is)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60028754T2 (de) 1999-11-12 2007-05-31 Abbott Laboratories, Abbott Park Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CA2398226A1 (en) * 2002-01-28 2003-07-28 Pfizer Inc. Increased-dosage nelfinavir tablet and method of making same
WO2005004868A1 (ja) 2003-07-15 2005-01-20 Arigen, Inc. 抗コロナウイルス剤
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2007517016A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
EP2586444B1 (en) * 2004-12-03 2019-09-25 Merck Sharp & Dohme Corp. Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate control composition
MY143784A (en) * 2005-09-23 2011-07-15 Hoffmann La Roche Novel dosage formulation
CN101330906B (zh) * 2005-12-14 2010-12-29 弗·哈夫曼-拉罗切有限公司 Hcv前药制剂
BRPI0619890A2 (pt) * 2005-12-14 2011-10-25 Hoffmann La Roche composição farmacêutica e processo para preparação de uma suspensão sólida
WO2008017867A2 (en) * 2006-08-10 2008-02-14 Cipla Limited Antiretroviral solid oral composition with at least one water insoluble polymer
CA2660086C (en) * 2006-08-16 2014-09-16 Novartis Ag Method of making solid dispersions of highly crystalline therapeutic compounds
EP2112925A4 (en) * 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
WO2008115442A1 (en) 2007-03-16 2008-09-25 Concert Pharmceuticals, Inc. Inhibitors of cholesterol ester transfer protein
AU2008242703B2 (en) * 2007-04-19 2011-08-18 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
WO2008133949A1 (en) 2007-04-25 2008-11-06 Concert Pharmaceuticals, Inc. Analogues of cilostazol
US8567657B2 (en) * 2007-04-30 2013-10-29 Mtj Consulting Services Inc. Coiled tubing with retainer for conduit
US9194512B2 (en) 2007-04-30 2015-11-24 Mark Andreychuk Coiled tubing with heat resistant conduit
EP4183787A1 (en) 2007-05-01 2023-05-24 Concert Pharmaceuticals Inc. Morphinan compounds
PL2357183T3 (pl) 2007-05-01 2015-12-31 Concert Pharmaceuticals Inc Związki morfinanu
MX2009011958A (es) 2007-05-01 2010-06-30 Concert Pharmaceuticals Inc Compuestos de morfina.
WO2008137461A1 (en) 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl) acetamides
SI2003120T1 (sl) 2007-06-12 2010-03-31 Concert Pharmaceuticals Inc Azapeptidni derivati kot inhibitorji hiv proteaze
WO2009051782A1 (en) * 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
AU2008312321A1 (en) * 2007-10-19 2009-04-23 Purdue Research Foundation Solid formulations of crystalline compounds
ITMI20080227A1 (it) * 2008-02-13 2009-08-14 Felice Vinati '' dispositivo di sicurezza per apparati di sollevamento a fune ''
BRPI0908107A2 (pt) 2008-02-29 2019-09-24 Concert Pharmaceuticals Inc composto derivado de xantina substituída, composição farmacêutica que compreende esse composto, métodos de tratamento de uma enfermidade ou condição em um paciente com necessidade do mesmo, método de tratamento de enfermidade crônica dos rins, do fígado, relacionada com diabetes e de claudicação intermitente
WO2009146310A1 (en) * 2008-05-28 2009-12-03 Concert Pharmaceuticals Inc. Deuterated tizanidine
WO2010019557A1 (en) * 2008-08-12 2010-02-18 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
ES2656444T3 (es) 2008-09-19 2018-02-27 Concert Pharmaceuticals, Inc. Compuestos de morfinano deuterados
HUE028956T2 (en) 2008-10-30 2017-01-30 Concert Pharmaceuticals Inc A combination of morphine compounds and an antidepressant for the treatment of pseudobulbar effects
WO2010062690A1 (en) 2008-10-30 2010-06-03 Concert Pharmaceuticals Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
WO2010053550A2 (en) 2008-11-04 2010-05-14 Anchor Therapeutics, Inc. Cxcr4 receptor compounds
WO2010065755A1 (en) 2008-12-04 2010-06-10 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8563554B2 (en) 2009-03-17 2013-10-22 Concert Pharmaceuticals, Inc. Deuterated pyrazinoisoquinoline compounds
WO2010138889A1 (en) 2009-05-28 2010-12-02 Concert Pharmaceuticals, Inc. Peptides for the treatment of hcv infections
WO2011005520A1 (en) 2009-06-23 2011-01-13 Concert Pharmaceuticals, Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
WO2011047315A1 (en) 2009-10-15 2011-04-21 Concert Pharmaceuticals, Inc. Subsitituted benzimidazoles
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (en) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
US20140018379A1 (en) 2010-02-18 2014-01-16 Concert Pharmaceuticals Inc. Pyrimidine derivatives
US9155795B2 (en) 2010-02-26 2015-10-13 Anchor Therapeutics, Inc. CXCR4 receptor compounds
EP3144296A1 (en) 2010-03-02 2017-03-22 Concert Pharmaceuticals, Inc. Deuterated tetrahydronaphthalene derivatives
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
WO2011157720A2 (en) * 2010-06-14 2011-12-22 Ratiopharm Gmbh Ivabradine-containing pharmaceutical composition with modified release
WO2012037060A1 (en) 2010-09-13 2012-03-22 Concert Pharmaceuticals Inc. Substituted azaindoles
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
WO2012065028A2 (en) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
JP2014506603A (ja) 2011-02-25 2014-03-17 コンサート ファーマシューティカルズ インコーポレイテッド ２−アミノ−ナフチリジン誘導体
WO2012129381A1 (en) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2012154728A1 (en) 2011-05-10 2012-11-15 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
PT2709986T (pt) 2011-05-18 2017-06-26 Concert Pharmaceuticals Inc Derivados deuterados de ivacaftor
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
FR2985177B1 (fr) * 2012-01-02 2016-04-01 Oreal Composition cosmetique solide aqueuse comprenant de l'alkylcellulose, au moins deux huiles non volatiles et au moins deux agents tensioactifs
CA2860740A1 (en) 2012-01-09 2013-07-18 Anchor Therapeutics, Inc. Apj receptor compounds
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2013155465A1 (en) 2012-04-13 2013-10-17 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2013159026A1 (en) 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Deuterated rigosertib
EA201492287A1 (ru) 2012-06-15 2015-07-30 Консерт Фармасьютикалс, Инк. Дейтерированные производные руксолитиниба
US10017445B2 (en) 2012-07-12 2018-07-10 Concert Pharmaceuticals, Inc. Deuterated idebenone
AU2013302519B2 (en) 2012-08-17 2017-11-02 Concert Pharmaceuticals, Inc. Deuterated baricitinib
WO2014078842A1 (en) 2012-11-19 2014-05-22 Concert Pharmaceuticals, Inc. Deuterated cftr potentiators
CA2895846A1 (en) 2012-12-20 2014-06-26 Concert Pharmaceuticals, Inc. Deuterated alk inhibitors
WO2014100733A1 (en) 2012-12-21 2014-06-26 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
AU2014237569B2 (en) 2013-03-15 2019-03-14 Concert Pharmaceuticals Inc. Inhibitors of the enzyme UDP-glucose: N-acyl-sphingosine glucosyltransferase
EA032094B1 (ru) 2013-03-15 2019-04-30 Консерт Фармасьютикалс, Инк. Дейтерированный палбоциклиб
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
EP3021861A1 (en) 2013-07-18 2016-05-25 Anchor Therapeutics, Inc. Apj receptor compounds
WO2015031741A1 (en) 2013-08-30 2015-03-05 Concert Pharmaceuticals, Inc. Deuterated derivatives of a thienotriazolodiazapine bromodomain-containing protein inhibitor
WO2015120393A1 (en) 2014-02-10 2015-08-13 Concert Pharmaceuticals, Inc. Substituted triazolobenzodiazepines
WO2015160913A1 (en) 2014-04-18 2015-10-22 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
PE20170664A1 (es) 2014-06-06 2017-06-10 Res Triangle Inst Agonistas del receptor de apelina(apj) y usos de los mismos
US10301273B2 (en) 2014-08-07 2019-05-28 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
US10301281B2 (en) 2014-12-11 2019-05-28 Merck Sharp & Dohme Corp. Crystal forms of a CCR5 antagonist
CN105769809A (zh) * 2014-12-23 2016-07-20 上海星泰医药科技有限公司 提高生物利用度的雷尼司他及其制备方法
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
US20180044375A1 (en) 2015-03-06 2018-02-15 Concert Pharmaceuticals, Inc. Deuterated emricasan
EP3277647A1 (en) 2015-03-31 2018-02-07 Vertex Pharmaceuticals (Europe) Limited Deuterated vx-661
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
WO2017020005A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for use in treating agitation
CA2994169A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
AU2016326441B2 (en) 2015-09-21 2021-11-25 Vertex Pharmaceuticals (Europe) Limited Administration of deuterated CFTR potentiators
US11267777B2 (en) 2015-11-19 2022-03-08 Concert Pharmaceuticals, Inc. Deuterated EPI-743
BR112018011784A2 (pt) 2015-12-09 2018-12-04 Res Triangle Inst agonistas aprimorados do receptor de apelina (apj) e usos dos mesmos
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
US10561659B2 (en) 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
CN115215801A (zh) 2016-07-04 2022-10-21 雅芳制药公司 氘代右美沙芬的合成方法
JP7178341B2 (ja) 2016-08-01 2022-11-25 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド タンパク質およびペプチドの送達のための粒子
WO2018160717A1 (en) 2017-02-28 2018-09-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
WO2018213609A1 (en) 2017-05-17 2018-11-22 Ausubel Frederick M Antibiotic compounds
CN111094282B (zh) 2017-05-19 2023-06-16 智优有限公司 瑞喹莫德的衍生物
EP3713557A1 (en) 2017-11-22 2020-09-30 Concert Pharmaceuticals Inc. Deuterated analogs of d-serine and uses thereof
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
US20230390292A1 (en) 2020-10-28 2023-12-07 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
CA3228505A1 (en) 2021-08-11 2023-02-16 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
WO2023018954A1 (en) 2021-08-12 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
WO2023215520A1 (en) 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5834472A (en) 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6001851A (en) 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0998271B3 (en) * 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
AU8145198A (en) * 1997-06-16 1999-01-04 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
ES2236943T3 (es) * 1997-09-19 2005-07-16 Shire Laboratories Inc. Perlas de disolucion solida.
ATE286720T1 (de) * 1999-11-12 2005-01-15 Abbott Lab Pharmazeutische formulierungen auf basis fester dispersionen
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation

Also Published As

Publication number Publication date
MA27018A1 (fr) 2004-12-20
ES2231717T3 (es) 2005-05-16
EP1390063B1 (en) 2004-11-17
HU229938B1 (en) 2015-01-28
HUP0401238A3 (en) 2012-09-28
NZ528689A (en) 2005-03-24
TWI234461B (en) 2005-06-21
ECSP034827A (es) 2003-12-24
JP2004527569A (ja) 2004-09-09
WO2002089835A2 (en) 2002-11-14
KR20040007523A (ko) 2004-01-24
JP4101661B2 (ja) 2008-06-18
MXPA03009971A (es) 2004-02-12
CN1255185C (zh) 2006-05-10
NO20034689L (no) 2003-10-20
BR0209325A (pt) 2004-07-20
CZ20033211A3 (cs) 2004-09-15
CA2444116C (en) 2009-01-20
BG108311A (bg) 2004-12-30
UA76463C2 (en) 2006-08-15
IL158306A (en) 2008-11-03
JO2401B1 (en) 2007-06-17
GT200200079A (es) 2002-12-05
PL366998A1 (en) 2005-02-07
HK1070285A1 (en) 2005-06-17
HRP20030873A2 (en) 2005-08-31
DE60201988D1 (de) 2004-12-23
WO2002089835A3 (en) 2003-05-01
NO20034689D0 (no) 2003-10-20
EP1390063A2 (en) 2004-02-25
KR100554816B1 (ko) 2006-02-22
HRP20030873B1 (en) 2006-04-30
IL158306A0 (en) 2004-05-12
CA2444116A1 (en) 2002-11-14
RS83503A (en) 2006-10-27
PA8544501A1 (es) 2002-11-18
US20030021840A1 (en) 2003-01-30
EA006627B1 (ru) 2006-02-24
MY128509A (en) 2007-02-28
US7014866B2 (en) 2006-03-21
DE60201988T2 (de) 2005-12-15
PE20021159A1 (es) 2002-12-20
PT1390063E (pt) 2005-03-31
CN1547484A (zh) 2004-11-17
GEP20053466B (en) 2005-02-25
SK14572003A3 (sk) 2004-12-01
HUP0401238A2 (hu) 2004-12-28
AR034320A1 (es) 2004-02-18
ATE282428T1 (de) 2004-12-15
EA200301166A1 (ru) 2004-04-29

Similar Documents

Publication Publication Date Title
IS7010A (is) Lyfjaform ókristallaðs nelfinavir mesylate
EE200300416A (et) Ravimvorm
NO20033384L (no) Farmasoytisk formulering
NO20033556L (no) Farmasöytiske formuleringer
FI20011478A (fi) Farmaseuttinen koostumus
FI20105657A (fi) Farmaseuttisia koostumuksia
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
ITMI20010748A0 (it) Composizioni farmaceutiche
EE05020B1 (et) Glburiidi ravimkoostis
NO20035315D0 (no) Farmasöytiske kombinasjoner
NO20035627D0 (no) Farmasöytisk formulering
FI20022128A (fi) Farmaseuttinen koostumus
NO20033162L (no) Farmasöytisk tablett omfattende paroksetinmesylat
DK1390063T3 (da) Farmaceutisk doseringsform af amorft nelfinavir-mesylat
EE200200689A (et) Ravimkoostised
NO20041236L (no) Farmasoytisk formulering
SE0103116D0 (sv) Pharmaceutical combination
SE0103565D0 (sv) Pharmaceutical formulation
SE0101171D0 (sv) Pharmaceutical formulation
SE0101325D0 (sv) Pharmaceutical formulation
SE0101326D0 (sv) Pharmaceutical formulation
SE0102957D0 (sv) Pharmaceutical formulation
SE0102069D0 (sv) Pharmaceutical formulation
SE0102572D0 (sv) Pharmaceutical formulation
FI5468U1 (fi) Farmaseuttinen koostumus